Pfizer Says FDA Approved RSV Vaccine ABRYSVO For Adults Aged 18 To 59 At Increased Risk For Disease
Portfolio Pulse from Benzinga Newsdesk
Pfizer's RSV vaccine, ABRYSVO, has received FDA approval for use in adults aged 18 to 59 who are at increased risk for respiratory syncytial virus (RSV) disease. This is the first RSV vaccine approved for adults under 50, based on Phase 3 trial data.
October 22, 2024 | 8:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer's RSV vaccine, ABRYSVO, has been approved by the FDA for adults aged 18 to 59 at increased risk for RSV. This approval, based on Phase 3 trial data, marks the first RSV vaccine for adults under 50.
The FDA approval of ABRYSVO for a new age group expands Pfizer's market potential and strengthens its position in the RSV vaccine space. This could lead to increased revenues and positive investor sentiment, likely boosting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100